You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
In PNAS this week: forward genetics-base analysis of retinal development, interactions of T cell receptors with neoantigens in colorectal cancer, and more.
Single-cell analysis, next-generation sequencing, and synthetic DNA have all been crucial to efforts to find antibodies that could neutralize SARS-CoV-2.
10x asked the US District Court for the Northern District of California to dismiss a suit, while another district court judge denied a 10x motion to dismiss.
At the Biology of Genomes virtual conference last week, several presentations focused on single-cell and spatial genomics data sets and how they could be complementary.
The Pleasanton, California-based firm reported $71.9 million in revenues but missed the consensus Wall Street estimates for quarterly revenues as well as loss per share.
In Nature this week: method to cluster cells based on single-cell RNA sequencing reads, synthetic genomics platform reconstructs SARS-CoV-2, and more.
Bio-Rad said it is withdrawing its previously issued annual revenue guidance given the uncertainties regarding the duration and impact of the COVID-19 pandemic.
Research institutions in the US and Europe will lead the studies, which will explore different aspects of COVID-19 such as host immune response.
Using single-cell RNA sequencing, researchers identified cells in mouse and human prostate tissues that appear to help regrow the gland after prostate cancer treatment.
In Nature this week: combining genome-wide association and transcriptome study data homes in on cells involved in brain disorders, and more.
According to Science, the US National Academy of Sciences is poised to eject two members accused of sexual harassment.
A UK study on mixing SARS-CoV-2 vaccines is expanding to include vaccines developed by additional companies, according to the Guardian.
In Nucleic Acids Research this week: machine learning approach to detect DNA-bound proteins, CRISPR-based method for activating specific gene targets, and more.
The FDA and CDC call for a pause in administering Johnson & Johnson's SARS-CoV-2 vaccine while reports of rare blood clots are looked into, reports the Wall Street Journal.